Proto-Oncogene Proteins p21(ras)
"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.
| Descriptor ID |
D016283
|
| MeSH Number(s) |
D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
|
| Concept/Terms |
Proto-Oncogene Proteins p21(ras)- Proto-Oncogene Proteins p21(ras)
- p21 c-ras
- c-ras, p21
- p21 c ras
- p21(c-ras)
- ras Proto-Oncogene Protein p21
- ras Proto Oncogene Protein p21
- Proto-Oncogene Proteins c-ras
- Proteins c-ras, Proto-Oncogene
- Proto Oncogene Proteins c ras
- c-ras, Proto-Oncogene Proteins
- Proto-Oncogene Protein ras
- Proto Oncogene Protein ras
- ras, Proto-Oncogene Protein
- ras Proto-Oncogene Product p21
- ras Proto Oncogene Product p21
- c-ras Proteins
- c ras Proteins
- p21(ras)
- Proto-Oncogene Protein p21(ras)
Proto-Oncogene Protein p21(c-Ha-ras)- Proto-Oncogene Protein p21(c-Ha-ras)
- p21 c-Ha-ras
- c-Ha-ras, p21
- p21 c Ha ras
- p21(c-Ha-ras)
- p21 c-H-ras
- c-H-ras, p21
- p21 c H ras
- c-Ha-ras p21
- c Ha ras p21
- p21, c-Ha-ras
Proto-Oncogene Protein p21(c-Ki-ras)- Proto-Oncogene Protein p21(c-Ki-ras)
- p21 c-Ki-ras
- c-Ki-ras, p21
- p21 c Ki ras
- p21(c-Ki-ras)
- p21 c-K-ras
- c-K-ras, p21
- p21 c K ras
- c-Ki-ras p21
- c Ki ras p21
- p21, c-Ki-ras
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".
This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 4 | 5 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 3 | 4 |
| 2003 | 2 | 3 | 5 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 4 | 5 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 4 | 6 | 10 |
| 2009 | 5 | 13 | 18 |
| 2010 | 4 | 13 | 17 |
| 2011 | 4 | 25 | 29 |
| 2012 | 6 | 24 | 30 |
| 2013 | 8 | 26 | 34 |
| 2014 | 6 | 21 | 27 |
| 2015 | 14 | 22 | 36 |
| 2016 | 14 | 15 | 29 |
| 2017 | 24 | 16 | 40 |
| 2018 | 15 | 9 | 24 |
| 2019 | 16 | 15 | 31 |
| 2020 | 19 | 16 | 35 |
| 2021 | 19 | 8 | 27 |
| 2022 | 5 | 27 | 32 |
| 2023 | 13 | 32 | 45 |
| 2024 | 15 | 15 | 30 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4932-4942.
-
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024 Nov 01; 14(11):2183-2208.
-
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024 Nov 01; 14(11):2135-2161.
-
Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia. Cancer Prev Res (Phila). 2024 Oct 01; 17(10):457-470.
-
Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):2950-2953.
-
Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Cell Rep Med. 2024 Sep 17; 5(9):101711.
-
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. Elife. 2024 Aug 30; 13.
-
The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Cancer Cell. 2024 Sep 09; 42(9):1494-1496.
-
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul 15; 30(14):2986-2995.
-
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2024 Jul 09; 15(1):5763.